Comparative Pharmacology
Head-to-head clinical analysis: NIZORAL versus VORICONAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NIZORAL versus VORICONAZOLE.
NIZORAL vs VORICONAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits fungal CYP51 (lanosterol 14α-demethylase), blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Inhibits fungal CYP450-dependent 14α-lanosterol demethylase, disrupting ergosterol synthesis and increasing membrane permeability.
Ketoconazole 200 mg orally once daily with food. For severe infections, increase to 400 mg once daily. Duration depends on indication.
Loading dose: 6 mg/kg IV every 12 hours for 2 doses, then maintenance 4 mg/kg IV every 12 hours; or 200–300 mg PO every 12 hours (400 mg PO every 12 hours for first 24 hours as loading dose if no IV).
None Documented
None Documented
Biphasic elimination: initial half-life ~2 hours, terminal half-life 6–10 hours in adults with normal hepatic function; prolonged in hepatic impairment.
Clinical Note
moderateVoriconazole + Tranilast
"The risk or severity of adverse effects can be increased when Voriconazole is combined with Tranilast."
Clinical Note
moderateVoriconazole + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Voriconazole is combined with Tolfenamic acid."
Clinical Note
moderateVoriconazole + Nimesulide
"The risk or severity of adverse effects can be increased when Voriconazole is combined with Nimesulide."
Clinical Note
moderateThe terminal elimination half-life is approximately 6 hours for CYP2C19 extensive metabolizers. In poor metabolizers (which occur in 15-20% of Asian populations), the half-life can be prolonged to up to 24 hours. Clinical context: Dosing adjustments may be necessary based on CYP2C19 genotype; the short half-life necessitates twice-daily dosing for most patients.
Approximately 70% of the dose is excreted unchanged in feces via biliary elimination, and about 20–35% is excreted in urine, with less than 1% as unchanged drug in urine.
Voriconazole is primarily metabolized in the liver via CYP2C19, CYP3A4, and to a lesser extent CYP2C9. Less than 2% of the dose is excreted unchanged in urine. Fecal excretion accounts for approximately 20% of the dose, with the remainder as metabolites in urine. Overall, renal elimination of unchanged drug is negligible, but metabolites are excreted renally.
Category C
Category D/X
Azole Antifungal
Azole Antifungal
Voriconazole + Risedronic acid
"The risk or severity of adverse effects can be increased when Voriconazole is combined with Risedronic acid."